Based on the remarkable expression of tenascin-C within lymph nodes of patients with B-cell NHL and Hodgkin lymphoma, radio-immunotherapy (RIT) approaches have been developed [15–19], and phase I clinical trials in different settings have shown both feasibility and therapeutic efficacy of tenascin-targeting therapeutic approaches [20, 21]. The gene discussed is TNC; the disease is B-cell non-Hodgkin lymphoma.